(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 November 2007 (15.11.2007)

PCT

(10) International Publication Number
WO 2007/130820 A3

(51) International Patent Classification:
C07D 413/14 (2006.01) *A61K 31/501* (2006.01)
C07D 401/14 (2006.01) *A61P 25/02* (2006.01)
C07D 403/14 (2006.01) *A61P 25/22* (2006.01)
A61K 31/513 (2006.01) *A61P 1/04* (2006.01)

(21) International Application Number:
PCT/US2007/067367

(22) International Filing Date: 25 April 2007 (25.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/797,659 5 May 2006 (05.05.2006) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; Se-151 85, S-SE-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WÅLLBERG, Andreas** [SE/SE]; AstraZeneca R & D, Mölndal SE-431 83, S-SE-431 83 Mölndal (SE). **NILSSON, Karolina** [SE/SE]; AstraZeneca R & D, Mölndal SE-431 83, S-SE-431 83 Mölndal (SE). **HOLM, Björn** [SE/SE]; AstraZeneca R & D, Mölndal SE-431 83, S-SE-431 83 Mölndal (SE). **NÅGÅRD, Mats** [SE/SE]; AstraZeneca R & D, Mölndal SE-431 83, S-SE-431 83 Mölndal (SE). **GRANBERG, Kenneth** [SE/SE]; AstraZeneca R & D, Mölndal SE-431 83, S-SE-431 83 Mölndal (SE). **SLASSI, Abdelmalik** [CA/CA]; 4780 Fulwell Road, Mississauga, Ontario L5M 7J7 (CA). **EDWARDS, Louise** [CA/CA]; 871 Chippenham Drive, Mississauga, Ontario L5H 3S6 (CA). **ISAAC, Methvin** [CA/CA]; 17 Reynolds Ave., Brampton, Ontario L6P 2C1 (CA). **XIN, Tao** [CA/CA]; 10 Comoq Ave., Woodbridge, Ontario L4H 2B1 (CA). **STEFANAC, Tomislav** (US).

(74) Agent: **MEIKLE, Andrew D.**; Birch, Stewart, Kolasch & Birch, LLP, P.O. Box 747, Falls Church, VA 22040-0747 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
13 March 2008

(54) Title: MGLUR5 MODULATORS I



(I)

(57) Abstract: The present invention is directed to novel compounds of Formula (I) for modulation of metabotropic glutamate receptors, in particular mGluRδ and their use in therapy, for instance disorders of the peripheral nervous system, reflux and irritable bowel syndrome.

WO 2007/130820 A3